News & Updates

A novel sensing device shows potential for detecting lung cancer before symptoms appear.

Treatment with nivolumab plus ipilimumab in the frontline setting provides clinically meaningful overall survival (OS) benefit compared with lenvatinib or sorafenib to patients with unresectable hepatocellular carcinoma (HCC) who were naive to systemic therapy, according to data from the phase III CheckMate 9DW study presented at ASCO GI 2025.

Taking aspirin contributes to a reduced risk of several gastrointestinal (GI) malignancies, such as colorectal cancer (CRC), liver cancer, stomach cancer, and pancreatic cancer, as shown by the results of a 20-year study presented at ASCO GI 2025. However, no association is seen with most non-GI cancers.

Addition of sintilimab to pemetrexed and platinum-based chemotherapy maintained or improved health-related quality of life (HRQoL) and symptoms compared with chemotherapy alone in first-line (1L) treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), according to a prespecified exploratory analysis of the phase III ORIENT-11 trial.

Short-course vaginal cuff brachytherapy (VCB) is just as efficacious as standard regimens for adjuvant treatment of endometrial cancer, yielding noninferior patient-reported outcomes without compromising disease control while having acceptable toxicity, according to the phase III, unblinded, multicentre SAVE trial.